contraindications to tirzepatide (Zepbound) for the Treatment of Obesity Drug profile of Tirzepatide (Diabetes

Ongoing virtual check-ins help track progress and adjust dosing when needed

In an FDA press release, John Sharretts, MD, deputy director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDAs Center for Drug Evaluation and Research said, Approval [of Wegovy] offers adults with obesity or [those who are] overweight a beneficial new treatment option to incorporate into a weight management program

How to think about protocol selection A practical way to choose among these patterns is to match the protocol to the level of complexity your lab can execute

A thorough consultation will determine your eligibility.

Published US norms are 15.01% (25.96%) for overall work impairment and 22.08% (28.33%) for activity impairment.Results relative to US norms were aligned across age and gender subgroups (Table)